Needham analyst Gil Blum lowered the firm’s price target on Mereo BioPharma (MREO) to $5 from $7 but keeps a Buy rating on the shares. The company announced that the Phase 3 Orbit study will continue towards a final analysis expected in Q4 after missing on its second interim, and this outcome represents the firm’s downside scenario, though Needham’s overall view on setrusumab’s ultimate likelihood of success remains unchanged, given that about 80% alpha spend is reserved for the final analysis, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MREO:
- Mereo BioPharma’s Phase 3 Study Progresses Smoothly
- Mereo Biopharma Group Plc: Buy Rating Maintained Amid Challenges and Promising Study Outcomes
- Promising Outlook for Mereo Biopharma’s Setrusumab Amid Phase 3 Trial Advances and Market Potential
- Closing Bell Movers: Ultragenyx slumps 25% on UX143 recommendation
- Ultragenyx, Mereo BioPharma receive DMC recommendation to continue Orbit study